OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine

Neurology

Volumn 77, Issue 15, 2011, Pages 1465-1472

  Lipton, R B ^a,b   Varon, S F ^c   Grosberg, B ^a,b   McAllister, P J ^d   Freitag, F ^e   Aurora, S K ^f   Dodick, D W ^g   Silberstein, S D ^h   Diener, H C ⁱ   DeGryse, R E ^c   Nolan, M E ^j   Turkel, C C ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c ALLERGAN INC   (United States)

^d Baylor University Medical Center ^*

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g MAYO CLINIC   (United States)

^h THOMAS JEFFERSON UNIVERSITY   (United States)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^j Albert Einstein College of Medicine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEADACHE; HEALTH CARE SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SECOND LOOK SURGERY; TRANSFORMED MIGRAINE; TREATMENT OUTCOME;

EID: 82955236200     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318232ab65     Document Type: Article

References (34)

1. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559-566.
2. Natoli J, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2009; 30:599-609.
3. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004;24(suppl 1):9-160.
4. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-746.
5. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 2003;43:336-342. (Pubitemid 36417763)
6. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache 2001;41:573-578. (Pubitemid 32619261)
7. Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2009;49:498-508.
8. Blumenfeld A, Varon S, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic mi- graineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-315.
9. Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and work impact of chronic migraine and episodic migraine. J Occup Environ Med 2010; 52:8-14.
10. Duru G, Auray JP, Gaudin AF, et al. Impact of headache on quality of life in a general population survey in France (GRIM2000 Study). Headache 2004;44:571-580. (Pubitemid 38780348)
11. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34:337-343. (Pubitemid 24217820)
12. Lovell BV, Marmura MJ. New therapeutic developments in chronic migraine. Curr Opin Neurol 2010;23:254-258.
13. Dodick DW, Turkel CC, DeGryse R, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebocontrolled phases of the PREEMPT clinical program. Headache 2010;50:921-936.
14. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-814.
15. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
16. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010;50:1406-1418.
17. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item shortform survey for measuring headache impact: the HIT-6. Qual Life Res 2003;12:963-974. (Pubitemid 37386625)
18. Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the headache impact test (HIT-6TM) across episodic and chronic migraine. Cephalalgia 2011;31: 357-367.
19. Martin M, Blaisdell B, Kwong JW, Bjorner JB. The Short- Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages. J Clin Epidemiol 2004; 57:1271-1278. (Pubitemid 40023147)
20. Bayliss MS, Batenhorst AS. The HIT-6™ A User's Guide. Lincoln, RI: QualityMetric Incorporated; 2002.
21. Coeytaux RR, Kaufman JS, Chao R, Mann JD, Devellis RF. Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test. J Clin Epidemiol 2006;59:374-380.
22. Cole JC, Lin P, Rupnow MF. Validation of the Migraine- Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment. Qual Life Res 2007;16:1231-1237. (Pubitemid 47357720)
23. Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW. MSQ: Migraine-Specific Quality-of-Life Questionnaire: further investigation of the factor structure. Pharmacoeconomics 1998;13:707-717. (Pubitemid 28247662)
24. Cole JC, Lin P, Rupnow MF. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version. Cephalalgia 2009;29:1180-1187.
25. Dodick DW, Silberstein S, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 2007;47:1398-1408. (Pubitemid 350209536)
26. Silberstein SD, Marmura MJ, Shaw J, Yu S. Headache prophylaxis with BoNTA: patient characteristics. Headache 2010;50:63-70.
27. Diener HC, Schorn CF, Bingel U, Dodick DW. The importance of placebo in headache research. Cephalalgia 2008;28:1003-1011.
28. Aurora S. Botulinum toxin type A for the treatment of migraine. Expert Opin Pharmacother 2006;7:1085-1095. (Pubitemid 43949946)
29. Hays RD, Farivar SS, Liu H. Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD 2005;2:63-67. (Pubitemid 40776225)
30. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484-495. (Pubitemid 351502554)
31. Elson CL, Maglinte GA, Rendas-Baum R, De Rosa M, Yang M, Varon SF. Validating use of the migraine-specific quality of life questionnaire version 2.1 (MSQ) across migraine disorders. Value Health 2010;13:A142. ISPOR abstract PND26.
32. Dworkin RH, Turk DC, McDermott MP, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 2009;146:238-244.
33. Dodick DW. Clinical practice: chronic daily headache. N Engl J Med 2006;354:158-165. (Pubitemid 43076713)
34. Matchar DB, Harpole L, Samsa GP, et al. The headache management trial: a randomized study of coordinated care. Headache 2008;48:1294-1310.